GlassScriptPhysician profile
Alberto Escallon
NPI 1184818452
$10,502.39
in general payments reported to CMS, 2019-2025
30 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,872 · 2020: $1,600 · 2021: $1,057 · 2022: $1,331 · 2023: $1,387 · 2024: $1,086 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,310.44 | 2019-2025 | Rexulti |
| Lundbeck LLC | $1,223.70 | 2019-2025 | Rexulti |
| Tris Pharma INC | $1,101.37 | 2019-2025 | Dyanavel Xr |
| Abbvie INC. | $853.12 | 2021-2023 | |
| Neos Therapeutics, LP | $774.19 | 2019-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $770.09 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $719.06 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $654.87 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.70 | 2022-2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $553.96 | 2019-2021 | |
| Corium, LLC | $336.58 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $268.17 | 2019-2022 | |
| Shire North American Group INC | $237.06 | 2019 | |
| Axsome Therapeutics, INC. | $150.56 | 2023-2025 | Auvelity |
| Vertical Pharmaceuticals, LLC | $128.50 | 2019-2025 | Relexxii |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $117.43 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $115.56 | 2019-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $78.87 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $73.99 | 2019-2020 | |
| Almatica Pharma LLC | $66.79 | 2023-2024 | Loreev Xr, Gralise |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $66.21 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $59.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $42.46 | 2023 | Quviviq |
| Bausch Health US, LLC | $38.86 | 2019-2020 | |
| Noven Therapeutics, LLC | $38.54 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $36.30 | 2025 | Fanapt |
| Alfasigma USA, INC. | $30.58 | 2021 | |
| Alkermes, INC. | $23.25 | 2024 | Lybalvi |
| Sage Therapeutics, LLC | $15.56 | 2023 | |
| Aytu Biopharma, INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Escallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.